Longevity research compounds are peptides and small molecules investigated in the peer-reviewed literature for their effects in cellular-aging, mitochondrial-energetics, telomerase, redox-balance, and lifespan models. Research has investigated the following compounds in the context of longevity- and aging-related preclinical and limited clinical models: NAD+, Epithalon, Glutathione, and MOTS-c.
The longevity-research literature is mechanistically diverse — sirtuin cofactor restoration (NAD+ and its precursors), telomerase activation and pineal-axis modulation (Epithalon), endogenous antioxidant repletion (glutathione), and mitochondrial-derived peptide signaling (MOTS-c). Lifespan-extension data in mammals are scarce; the published evidence base in this category is predominantly preclinical, with several compounds having early-phase human trial data for narrower indications (frailty, age-related metabolic decline).
What Peer-Reviewed Research Investigates in This Category
Longevity-category research in the published literature investigates several mechanistic targets:
- NAD+ metabolism and sirtuin signaling — studies of NAD+, its precursors NMN and NR, and downstream sirtuin (SIRT1, SIRT3) activity in age-related decline of mitochondrial function. Published clinical trials of oral NMN and NR have reported NAD+ elevation in human blood and tissue.
- Telomerase activation and the pineal axis — Khavinson group research on the synthetic tetrapeptide Epithalon (Ala-Glu-Asp-Gly) in rodent aging models and limited human studies of melatonin secretion, lipid profile, and reported lifespan parameters.
- Cellular redox and antioxidant capacity — investigations of glutathione (GSH), the principal intracellular thiol antioxidant, in oxidative-stress, hepatic, and neurodegenerative models.
- Mitochondrial-derived peptides — endogenous mitokines (MOTS-c, humanin) investigated for insulin-sensitivity, metabolic-homeostasis, and exercise-mimetic effects in mice.
Few compounds in this category have demonstrated mammalian lifespan extension in the published literature. Most “longevity” claims in the broader peptide market extrapolate from biomarker effects (NAD+ levels, telomere length, GSH concentrations) to inferred aging outcomes — a translation step the peer-reviewed literature does not yet support.
Compounds Studied in Longevity Research
NAD+
Nicotinamide adenine dinucleotide (NAD+) is an endogenous coenzyme essential for redox reactions, sirtuin activity, PARP signaling, and CD38-mediated calcium signaling. NAD+ levels decline with age in multiple tissues. Published clinical trials of the precursors nicotinamide mononucleotide (NMN; Yoshino et al., Science 2021) and nicotinamide riboside (NR; Martens et al., Nat Commun 2018) have reported increases in blood NAD+ following oral administration.1 Research on injected/infused NAD+ itself is comparatively limited.
Epithalon
Epithalon (Epitalon; Ala-Glu-Asp-Gly; CAS 307297-39-8) is a synthetic tetrapeptide developed by V. Kh. Khavinson’s group at the St. Petersburg Institute of Bioregulation and Gerontology. Khavinson et al. (2003) and follow-up publications reported telomerase activity induction in human somatic cells in vitro and effects on melatonin rhythm and reported survival in elderly Russian cohorts.2 The published literature is overwhelmingly Russian-language; Western peer-reviewed replication of telomerase-activation and lifespan claims is limited.
Glutathione
Glutathione (γ-Glu-Cys-Gly; GSH) is the principal endogenous intracellular thiol antioxidant. Reduced glutathione participates in xenobiotic conjugation, peroxide reduction, and disulfide exchange. The clinical-research literature on glutathione spans hepatic (acetaminophen toxicity, fatty liver disease), pulmonary (cystic fibrosis), and neurodegenerative (Parkinson’s disease) indications, with N-acetylcysteine (NAC) — a glutathione precursor — being the more clinically established intervention in most of these contexts.3
MOTS-c
MOTS-c (Mitochondrial Open Reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within mitochondrial DNA. Lee et al. (2015, Cell Metab) characterized MOTS-c as a regulator of insulin sensitivity and metabolic homeostasis in mice, with subsequent work investigating exercise-mimetic and age-related metabolic-decline effects.4 Also classified under metabolic research.
Frequently Asked Research Questions
What peptides and compounds are studied for longevity research?
The peer-reviewed longevity-research literature focuses on NAD+ (and its precursors NMN and NR), the synthetic tetrapeptide Epithalon, the endogenous antioxidant glutathione, and the mitochondrial-derived peptide MOTS-c. Mechanistic targets include sirtuin cofactor restoration, telomerase activation, cellular redox balance, and mitokine signaling.
Has any of these compounds been shown to extend lifespan in humans?
No. No compound in this category has demonstrated lifespan extension in humans in peer-reviewed prospective controlled trials with mortality as the primary endpoint. Reported “longevity” effects in the published literature are typically biomarker effects — for example, raised NAD+ levels, improved glutathione status, or telomerase-activity changes — that are mechanistically related to aging biology but not the same as a demonstrated mortality benefit.
What is the difference between NAD+, NMN, and NR?
NAD+ is the active coenzyme. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors that are converted to NAD+ intracellularly. Published human clinical trials of oral NMN and NR have reported elevation of blood and tissue NAD+ levels. Research on parenteral NAD+ administration is more limited in the peer-reviewed literature than the consumer market would suggest.
Is Epithalon’s telomerase-activation effect peer-reviewed?
Khavinson and colleagues have published telomerase-activation findings for Epithalon, primarily in Russian-language peer-reviewed journals. Independent Western peer-reviewed replication of in vitro telomerase-induction and any lifespan-related claims is limited. Researchers evaluating the Epithalon literature should be aware of this asymmetric publication base.
Why is MOTS-c classified under both metabolic and longevity research?
MOTS-c is investigated in two overlapping literature streams: its insulin-sensitivity and adipose-tissue effects place it within metabolic research, while its mitochondrial origin and age-related decline place it within longevity research. The same publications often address both. It appears in both category hubs to support researchers approaching it from either angle.
References
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229. PubMed. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PubMed.
- Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590–592. PubMed.
- Lu SC. Glutathione synthesis. Biochim Biophys Acta. 2013;1830(5):3143–3153. PubMed.
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. PubMed.
